{"schema_version":"1","generated_at":"2026-11-06T18:39:11.372Z","data_as_of":null,"url":"https://www.findmykol.com/kol/rushdia-yusuf","json_url":"https://www.findmykol.com/kol/rushdia-yusuf/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"rushdia-yusuf","name":"Rushdia Yusuf","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Merck & Co.","institution_url":"https://www.findmykol.com/institution/merck-co","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1396782348","openalex":"A5109250723"},"summary":"Rushdia Yusuf is an Oncology physician affiliated with Merck & Co.. OpenAlex indexes 62 publications with 3,438 citations (h-index 19).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":62,"cited_by_count":3438,"h_index":19,"latest_activity_year":2026,"source":"works"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"POSTER: ABCL-313: waveLINE-011: Zilovertamab Vedotin Plus R-CHP vs Polatuzumab Vedotin Plus R-CHP as First-Line Therapy in Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)01087-6","status":"verified"},{"title":"ABCL-313: waveLINE-011: Zilovertamab Vedotin Plus R-CHP vs Polatuzumab Vedotin Plus R-CHP as First-Line Therapy in Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma","year":2026,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/s2152-2650(26)02554-1","status":"verified"},{"title":"waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps7104","status":"verified"},{"title":"WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.7005","status":"verified"},{"title":"Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-5479","status":"verified"}],"source":"works"},"contact":{"address_1":"GRB 740, 55 FRUIT STREET","address_2":"MASS GENERAL HOSPITAL","city":"Boston","state":"MA","zip":"02114","phone":"617-726-2000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1396782348","source":"identity"},"similar":[{"name":"Ednan Bajwa","slug":"ednan-bajwa","institution":"Merck & Co.","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/ednan-bajwa","json_url":"https://www.findmykol.com/kol/ednan-bajwa/profile.json"},{"name":"Annaswamy Raji","slug":"annaswamy-raji","institution":"Merck & Co.","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/annaswamy-raji","json_url":"https://www.findmykol.com/kol/annaswamy-raji/profile.json"},{"name":"Ritu Valiyil","slug":"ritu-valiyil","institution":"Merck & Co.","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/ritu-valiyil","json_url":"https://www.findmykol.com/kol/ritu-valiyil/profile.json"},{"name":"Vassiliki Karantza-Wadsworth","slug":"vassiliki-karantza-wadsworth","institution":"Merck & Co.","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/vassiliki-karantza-wadsworth","json_url":"https://www.findmykol.com/kol/vassiliki-karantza-wadsworth/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2024-10-21","provider_certified":"2024-10-21","collected_at":"2026-11-05T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}